Formation of neutralizing antibodies after treatment with human calcitonin.
OBJECTIVE
Calcitonin is used for the treatment of Paget's disease of bone, hypercalcemia, and postmenopausal osteoporosis. The formation of antibodies against heterologous calcitonins, such as salmon calcitonin (sCT), has been described frequently. Neutralizing effects of these antibodies have been demonstrated in many cases. As far as antibody formation against human calcitonin (hCT) is concerned, only a single case has been reported in the literature; however, investigations concerning the biologic activity of the antibodies were not performed. We have now assessed the sera of 33 patients treated with hCT for postmenopausal osteoporosis for a period of at least 12 months to evaluate the occurrence of hCT-binding and hCT-neutralizing antibodies.


METHODS
Binding antibodies were detected by incubation of patient sera with 125I-labeled hCT; neutralizing activity was assessed in an in vitro bioassay that measured the impairment of the hCT-induced cyclic adenosine monophosphate (cAMP) formation in the human breast cancer cell line T47D.


RESULTS
Prior to hCT treatment, none of the patients showed evidence of the presence of either binding or neutralizing antibodies. During the course of treatment, binding antibodies occurred in a single patient. These antibodies had a neutralizing activity characterized by 15% impairment of cAMP formation after 6 months and 27% impairment after 12 months of treatment compared with pretreatment control values. The neutralizing effect observed in this particular patient was comparatively mild compared with the effects seen after the formation of neutralizing antibodies against sCT, so major clinical sequelae were not expected in this patient. This may be due to the lower antigenicity of hCT as compared with sCT.


CONCLUSIONS
Although antibody formation against hCT is a rare phenomenon, we nonetheless recommend monitoring of postmenopausal osteoporosis patients treated with sCT or hCT for neutralizing antibody formation in order to evaluate the therapeutic effect of treatment.
Grauer
A
A
Department of Internal Medicine 1, Endocrinology and Metabolism, University of Heidelberg, Germany.
Reinel
H H
HH
Lunghall
S
S
Lindh
E
E
Ziegler
R
R
Raue
F
F
D000368:Aged; D000369:Aged, 80 and over; D000917:Antibody Formation / Q000276:immunology; D001681:Biological Assay; D002116:Calcitonin / Q000276:immunology* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007457:Iodine Radioisotopes; D008875:Middle Aged; D009500:Neutralization Tests; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy / Q000276:immunology
D007457:Iodine Radioisotopes; D002116:Calcitonin